Baricitinib in chronic kidney disease: an exploratory analysis integrating network toxicology, molecular docking and pharmacovigilance.

ABSTRACT:

Background

Chronic kidney disease (CKD) presents a major global health challenge due to ineffective therapies against progressive renal fibrosis. Baricitinib, a selective JAK1/JAK2 inhibitor, has anti-inflammatory and anti-fibrotic potential, yet its mechanistic basis and safety implications in CKD require further exploration.

Methods

An integrated strategy was employed, combining network toxicology across multiple databases, protein-protein interaction network analysis and molecular docking. Real-world safety was evaluated by analyzing adverse event (AE) reports from FDA Adverse Event Reporting System (FAERS) (2018-2024), capturing safety data across all approved indications for baricitinib by calculating reporting odds ratios (RORs) and proportional reporting ratios (PRRs)

SUBMITTER: Zheng R 

PROVIDER: S-EPMC12827112 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature